Bio-Techne (TECH) Q1 Earnings call transcript Oct 30, 2025
1min read In the latest earnings call for the first quarter of fiscal year 2025, Bio-Techne executives outlined the company's strategic initiatives and financial performance. The call, led by President and CEO, Kim Kelderman, and Chief Financial Officer, Jim Hippel, highlighted several key themes and trends that underscore the company's commitment to innovation, sustainability, and growth.
Strong Start to Fiscal Year 2025
Bio-Techne reported a 4% year-over-year organic revenue growth in the first quarter of fiscal year 2025. This growth was driven by the continued stabilization of the biopharma end markets and excellent execution by the Bio-Techne team. The company's growth pillars, including molecular diagnostics and spatial biology platforms, as well as its proteomic analysis franchise, all outperformed in constrained end markets.
Focus on Sustainability
The call also highlighted Bio-Techne's commitment to environmental, social, and governance (ESG) initiatives. The company issued its fourth iteration of its corporate sustainability report (CSR), showcasing significant progress in reducing greenhouse gas emissions. These reduction targets will be evaluated by the science-based targets initiative in 2026, demonstrating Bio-Techne's dedication to a sustainable future.
Strategic Acquisitions and Synergies
In terms of strategic moves, Bio-Techne announced its plans to acquire the remaining stake in its scale-ready joint venture partner, Wilson Wolf, by the end of calendar 2027. This acquisition will further strengthen Bio-Techne's position in the cell therapy and bioreactor markets, positioning the company for future growth in the high-growth industry.
Innovation and Product Development
Bio-Techne also highlighted its focus on innovation, with the launch of new products and initiatives. The company's proteomic and spatial biology tools play a crucial role in scientific research and healthcare, especially in the emerging spatial biology field. The latest addition to its Simple Western franchise, LEO, a high-throughput automated western blotting system, has shown significant customer interest and is expected to launch in the second half of fiscal year 2025.
Financial Performance and Outlook
From a financial perspective, Bio-Techne's first quarter performance was largely in line with expectations, with adjusted EPS of $0.42 compared to $0.41 in the prior year quarter. The company generated $63.9 million from operations and returned $12.7 million in dividends to shareholders. Looking ahead, Bio-Techne anticipates steady improvement in operating margins and continued focus on cost containment and productivity initiatives.
Conclusion
Bio-Techne's first quarter earnings call for fiscal year 2025 underscored the company's strong start, strategic initiatives, and commitment to sustainability and innovation. With a focus on growth pillars, strategic acquisitions, and product development, Bio-Techne is well-positioned for future success. As the company continues to navigate market challenges, its dedication to delivering innovative solutions for its customers remains a key driver of its growth prospects.
